Abstract

Oral cancer is one of the most common malignancies worldwide. The treatment options remain to be surgery, radiation, and/or chemotherapy. In spite of all modern technologies and advances in research, the survival rate of patients with oral cancer has not improved. Among the various chemotherapeutic agents, cisplatin is a commonly used drug for oral squamous cell carcinoma as induction, adjuvant, neoadjuvant, or palliative chemotherapy. This article reviews on the clinical trials done with cisplatin for oral cancer. Based on the review, it is suggestive that cisplatin is superior to other chemotherapy agent, but there is no advantage of cisplatin when used as an adjuvant or neoadjuvant therapy to surgery.